Isolated adrenocorticotropic hormone deficiency associated with nivolumab therapy
- 8 September 2016
- journal article
- Published by Wiley in The Journal of Dermatology
- Vol. 44 (4), e70
- https://doi.org/10.1111/1346-8138.13571
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Management of side effects of immune checkpoint blockade by anti‐CTLA‐4 and anti‐PD‐1 antibodies in metastatic melanomaJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2016
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with OutcomesClinical Cancer Research, 2016
- Neurological symptoms in a patient with isolated adrenocorticotropin deficiency: case report and literature reviewBMC Endocrine Disorders, 2016
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialThe Lancet Oncology, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015